Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of the combined company. Kenvue shareholders will own about 46% in what is one of the largest corporate takeovers this year.

State Attorney General Ken Paxton parroted claims by the Health Secretary which have been strongly refuted by medical professionals

(Reuters) -Kleenex maker Kimberly-Clark said on Monday it will buy Kenvue for more than $40 billion in a landmark deal for the consumer sector, as the Tylenol maker grapples with White House scrutiny and choppy demand.